Orchid Chemicals and Pharmaceuticals Ltd has received formal approval from the Canadian TPD (Therapeutic Product Directorate) for two of its ANDS (Abbreviated New Drug Submission) applications. These approvals correspond to two generic formulations, cefoxitin and ceftriaxone. These products are covered under the exclusive marketing arrangement that the company has with the leading Canadian generics major, Apotex.

Commenting on this development K Raghavendra Rao, managing director, of the company said, "We are happy to foray into the Canadian generic segment with these approvals. With limited competition and a niche injectable product offering, we are confident of a sustainable revenue base froth Canada. Given the track record of Apotex in garnering a major market share in the generic antibiotic injectable market in the US, we are optimistic that they would be able to replicate the same in the Canadian market too."

Going forward, the company would be enhancing its market presence further in Canada by launching other generic formulations in the cephalosporin and other product segments based on Specific product filings and approvals.